Dr Mathilda Wilding
MBBS, FRACP (MedOnc, ClinGen), BMedSi, Cancer Geneticist
I am passionate about helping families clarify their cancer risk and empowering them to prevent cancer or to detect cancer early
Special clinical interest in cancer.
Dr Mathilda Wilding has been working in the field of cancer genetics since 2015. Mathilda is qualified as a specialist in medical oncology (cancer treatment) and clinical genetics. Mathilda is one of only a few doctors in Australia to have achieved both of these qualifications and has been appointed as a cancer genetics specialist at Royal North Shore Hospital, Sydney.
Mathilda is a Fellow of the Royal College of Physicians (FRACP) and a member of the Human Genetics Society of Australia (HGSA). She is a member of the adult and paediatric cancer genetics reference committees for the National Cancer Institute (eviQ) guidelines. She is involved in developing evidence-based genetic testing and risk management guidelines, that are used Nationally and Internationally, to guide genetic testing and the management of individuals with an inherited cause of cancer.
A dedicated teacher, she supervises and mentors training doctors and genetic counsellors from hospitals across NSW.
Mathilda’s main goal is to be a caring, respectful clinician, to listen to your concerns and provide clear and understandable explanations.
For Frequently Asked Questions and general information on cancer genetics please visit: www.preventcancer.com.au
- Human Genetics Society of Australia (HGSA)
- Cancer Genetics Reference Committees for the National Cancer Institute (eviQ)
- Fellow of Royal Australian College of Physicians (FRACP)
- Crook, A., Kwa, R., Ephraums, S., Wilding, M., Thiyagarajan, L., Fleming, J., ... & Berman, Y. (2021). The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1. Familial cancer, 1-13.
- Benn, D. E., Zhu, Y., Andrews, K. A., Wilding, M., Duncan, E. L., Dwight, T., ... & Clifton-Bligh, R. J. (2018). Bayesian approach to determining penetrance of pathogenic SDH variants. Journal of medical genetics, 55(11), 729-734.